Author

S. Colborne

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:experimental assay· 4 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 3 Research Focus:differential expression· 3 Research Focus:gene regulatory network inference· 3 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2

Frequent Co-Authors

G. B. Morin· 5 shared G. L. Negri· 2 shared M. Hirst· 2 shared A. Cheng· 1 shared A. Dawson· 1 shared A. El-Naggar· 1 shared A. Haegert· 1 shared A. J. Lazar· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

G. B. Morin

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

ASPSCR1-TFE3 reprograms transcription by organizing enhancer loops around hexameric VCP/p97

A. Pozner, S. P. Verma, L. Li, S. Wang, J. J. Barrott, M. L. Nelson, J. S. E. Yu, G. L. Negri, S. Colborne, C. S. Hughes, J.-F. Zhu, S. L. Lambert, L. S. Carroll, K. Smith-Fry, M. G. Stewart, , K. B. Jones

This study identifies VCP/p97 as an obligate co-factor of ASPSCR1-TFE3, showing it organizes enhancer loops to drive oncogenic transcription in ASPS and RCC.

bioRxiv · Sep 29, 2023Cancer Biology

Loss of FBXO11 function establishes a stem cell program in acute myeloid leukemia through dysregulation of the mitochondrial LONP1

A. Y.-C. Mo, H. Kincross, X. Wang, L. Y.-T. Chang, G. Duns, F. Mey, Z. Zhu, H. Kwan, T. Lau, T. R. Docking, J. Tran, S. Colborne, S.-W. G. Cheng, S. Huang, N. Gharaee, , A. Karsan

This study identifies FBXO11 loss as a driver of AML by promoting a stem cell program through mitochondrial dysregulation.

bioRxiv · Sep 10, 2022 · PreprintCancer Biology

YB-1 IS REQUIRED FOR THE GENESIS AND METASTATIC CAPACITY OF HUMAN BREAST CANCER

S. Lefort, A. El-Naggar, S. Tan, S. Colborne, G. L. Negri, D. Pellacani, M. Hirst, B. Gusterson, G. B. Morin, P. H. Sorensen, C. J. Eaves

This study shows YB-1 is essential for human breast cancer growth and metastasis, as its knockdown inhibits tumor formation and lung colonization in mice.

bioRxiv · Nov 20, 2020 · PreprintCancer Biology

Multiomics Characterization of Potential Therapeutic Vulnerabilities in Low-grade Serous Ovarian Carcinoma

R. Shrestha, M. L. Fernandez, A. Dawson, J. Hoenisch, S. Volik, Y.-Y. Lin, S. Anderson, H. Kim, A. Haegert, S. Colborne, B. McConeghy, R. H. Bell, S. Brahmbhatt, G. E. DiMattia, S. Le Bihan, , M. S. Carey

This study uses multiomics analysis of LGSOC cell lines to identify therapeutic vulnerabilities and biomarkers for MEK inhibitor efficacy.

bioRxiv · Jun 18, 2020 · PreprintCancer Biology

Arginine depletion through ADI-PEG20 to treat argininosuccinate synthase deficient ovarian cancer, including small cell carcinoma of the ovary, hypercalcemic type

J. X. Ji, D. R. Cochrane, B. Tessier-Cloutier, S. Chen, G. Ho, K. V. Pathak, I. Alcazar, D. Farnell, S. Leung, A. Cheng, C. Chow, S. Colborne, G. Luca Negri, F. Kommoss, A. N. Karnezis, , D. G. Huntsman

This paper identifies ASS1 deficiency in rare ovarian cancers and shows that ADI-PEG20 inhibits tumor growth in ASS1-deficient models.

bioRxiv · Nov 17, 2019 · PreprintCancer Biology